Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Shareholders of Antibe Holdings Inc.?

<< Previous

Bullboard Posts

Next >>

Post by MasterAlgaeon Dec 18, 2020 9:17am

162 Views

Post# 32138772

Shareholders of Antibe Holdings Inc.?

The public company needs to acquire all the IP rights from the holding company.

So in one way this could be the exit for management and new managemnt team could slide in and take this towards the end.

The owners of the holding company are at the front of the line for a payout....fair-enough I guess.

What would you hold out for? 20 million?

<< Previous

Bullboard Posts

Next >>

Anaergia expands relationship with PepsiCo